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Background: Doxorubicin has a broad spectrum of anticancer activity, but its clinical 
  application is limited due to serious side effects. The aim of this study was to explore a novel 
drug delivery system based on titanium dioxide (TiO2) nanoparticles for its potential role in 
enhancing the anticancer efficacy of doxorubicin while reducing its side effects.
Methods and results: Doxorubicin was loaded into TiO2 nanoparticles by forming complexes 
with the transition metal, titanium, to construct doxorubicin-titanium dioxide (DOX-TiO2) nano-
composites as a drug delivery system. The anticancer activity of the DOX-TiO2 nanocomposites 
was demonstrated by MTT assay, and the possible signaling pathway was explored by Western 
blot. In human SMMC-7721 hepatocarcinoma cells, our observations demonstrated that this 
drug delivery system markedly increased the efficiency of drug per dosage and decreased the 
IC50, resulting in anticancer efficacy enhancement and side effect attenuation.
Conclusion: Such a doxorubicin delivery strategy is promising in cancer therapy. Apoptosis 
may contribute to the mechanism, due to protein expression of Bcl-2 being downregulated and 
that of Bax and caspase 3 being upregulated.
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Introduction
Doxorubicin is one of the most effective anticancer drugs to date, with a wide scope of 
activity in human cancers, including acute lymphoblastic leukemia, breast carcinoma, 
ovarian carcinoma, and hepatocellular carcinoma.1 However, its clinical application is 
limited by its harmful side effects, the most significant of which is its cardiotoxicity, which 
can lead to cardiomyopathy and congestive heart failure.2 Overcoming side effects is the 
greatest challenge for doxorubicin before its clinical application. Therefore, efforts have 
been made to develop new delivery techniques to reduce side effects, which could alter 
its biodistribution, enhance its deposition at the tumor sites, and improve its therapeutic 
efficacy. The availability of a nanocarrier drug delivery system is an exciting develop-
ment that holds the promise of a fundamental change in cancer chemotherapy.3,4
A variety of organic5,6 and inorganic7–10 biomaterials have been explored for drug 
delivery purposes, among which the semiconductor nanomaterials, such as titanium 
dioxide (TiO2) nanoparticles and zinc oxide nanorods, are attracting an increasing 
level of attention.11–15 Barick et al reported a method for entrapping drugs at sites 
capable of complexing with transition metal ions and suggested that drug release is 
dependent on the pH of the medium and the nature of the materials which encapsulate 
the drug.12 It is also suggested that this general strategy could be readily extended to 
other inorganic carriers.12International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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In light of these observations, we explored a novel drug 
delivery system based on TiO2 nanoparticles for doxorubicin 
by a simple and easy scheme to enhance its chemotherapeu-
tic efficiency and reduce the side effects. To the best of our 
knowledge, no study of doxorubicin has been carried out 
using TiO2 nanoparticles for anticancer efficacy enhance-
ment and side effect attenuation. In this study, doxorubicin 
was loaded on TiO2 nanoparticles which are chemically 
stable, environmentally friendly, and noncytotoxic,13,14 to 
form nanocomposites of doxorubicin-loaded titanium diox-
ide nanoparticles (DOX-TiO2) for a drug delivery system. 
Their encapsulation efficiency and loading efficiency was 
assessed by high-pressure liquid chromatography. We then 
identified the cytotoxic effects of DOX-TiO2 in human 
SMMC-7721 hepatocarcinoma cells. The mechanism of 
anticancer efficacy enhancement and side effect attenuation 
were also investigated.
Materials and methods
Main chemicals and apparatus
Doxorubicin was purchased from Hisun Phamaceuticals, 
Zhejiang, China, and a stock solution was freshly prepared 
and stored in the dark at 4°C. Phosphate-buffered solution 
(0.1 M, pH 7.2) was prepared with double-distilled water. 
TiO2 nanoparticles purchased from Degussa Corporation 
(Parsippany, NJ) were suspended in sterilized phosphate-
buffered solution. Monoclonal antibodies, including Bax, 
Bcl-2, caspase 3, and β-actin, were purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA). The horseradish 
peroxidase-conjugated IgG antibody was obtained from Nan-
jing KeyGenBiotech Inc (Nanjing, China). 4, 6-diamidino-
2-phenylindole (DAPI) and 3-(4, 5-dimethylthiazol-2-yl)-2, 
5-diphenyltetrazolium bromide (MTT) were obtained from 
Sigma (St Louis, MO) and stored in the dark. All other 
reagents were of analytical grade. The optical density at 
492 nm was recorded by a multiwell spectrophotometer 
reader (DG5033A, Nanjing, China). Transmission electron 
microscope images were obtained using a JEM-2100 trans-
mission electron microscope (JOEL, Peabody, MA).
Construction of DOX-TiO2 
nanocomposites
For a typical drug loading experiment, a 2 mL aqueous 
solution of doxorubicin (2 mg/mL) was added to a 1 mL 
aqueous suspension of TiO2 nanoparticles (10 mg/mL). The 
reaction mixture was kept overnight in the dark to construct 
the nanocomposites of DOX-TiO2, which acted as a drug 
delivery system. The zeta potential of the TiO2   nanoparticles 
and DOX-TiO2 nanocomposites was determined to   confirm 
the interaction of doxorubicin loading onto the TiO2 
  nanoparticles. Doxorubicin-loaded TiO2 nanoparticles 
were separated from the free-standing drug molecules by 
centrifugation at 5000 g for 20 minutes and the supernatant 
was determined by high-pressure liquid chromatography, 
allowing estimation of the drug encapsulation efficiency and 
loading efficiency. The encapsulation efficiency and loading 
efficiency were calculated using the following equations:
Encapsulation efficiency = (amount of drug in drug-loaded 
nanoparticles/initial amount of drug) × 100%
Loading efficiency = (amount of drug in drug-loaded  
nanoparticles/total amount of drug-loaded 
nanoparticles) × 100%
Cell culture
Human SMMC-7721 hepatocarcinoma cells were obtained 
from the Shanghai Institute of Cells, Chinese Academy of 
Sciences, and maintained in RPMI 1640 (Gibco, Grand Island, 
NY) medium supplemented with 10% heat-inactivated fetal 
bovine serum, 100 U/mL penicillin, and 100 µg/mL strepto-
mycin (Sigma) at 37°C in humidified air with 5% CO2.
Assay of anticancer activity
The cytotoxicity of the TiO2 nanoparticles, doxorubicin, and 
DOX-TiO2 was studied in the human SMMC-7721 hepa-
tocarcinoma cell line by MTT assay. Cells at 1 × 105/mL 
were seeded in 96-well plates and incubated for 24 hours. 
The growth medium was then replaced with 200 µL of the 
prepared medium containing free doxorubicin or DOX-TiO2, 
in which the doxorubicin concentration was 0, 0.125, 0.25, 
0.5, and 1 µg/mL. The cells were also treated with TiO2 nano-
particles alone to evaluate cytotoxicity. Untreated cells were 
used as the control group. The cells were further incubated 
for 48 hours, and the relative anticancer activity was assessed 
using MTT assays. In brief, MTT solutions were added after 
the treatments and incubated for an additional four hours. 
Dimethyl sulfoxide was added to solubilize the formazan 
crystal, and optical density at 492 nm was recorded. The cell 
viability fraction (%) was calculated as follows:
OD492 nm in test cells/OD492 nm in control cells × 100%
Western blot analysis
Expression of apoptosis-related proteins was detected by 
Western blot after the different treatments. In brief, total 
protein was isolated and subjected to sodium dodecyl sul-
fate polyacrylamide gel electrophoresis, and transferred to International Journal of Nanomedicine 2011:6
Figure  1  Transmission  electron  microscope  image  of  magnetic  titanium  oxide 
nanoparticles.
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Figure 2 size distribution histogram of titanium oxide nanoparticles.
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Figure  3  Photographic  image  (A)  and  the  schematic  representation  (B)  of 
doxorubicin loading onto the TiO2 nanoparticles through the formation of DOX-
TiO2 nanocomposites. 
Abbreviations: DOX, doxorubicin; TiO2, titanium dioxide; Nps, nanoparticles.
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a polyvinylidene fluoride membrane. After being blocked, 
the membrane was incubated with primary monoclonal 
antibodies, either anti-Bax, Bcl-2, caspase 3, or anti-β-actin 
overnight at 4°C, and subsequently incubated with horserad-
ish peroxidase-conjugated IgG antibody as the secondary 
antibody for one hour at room temperature. The protein 
bands were detected by an enhanced ECL detection system 
(Amersham, UK). After normalization by the corresponding 
expression of β-actin, protein expression levels of caspase 3, 
Bax, and Bcl-2 were determined by densitometry scans.
statistical analysis
All the data are presented as the mean ± standard deviation. 
The F-test was used for significance testing, and P , 0.05 was 
considered to be statistically significant. All tests were per-
formed using SPSS version 13.0 (SPSS Inc, Chicago, IL).
Results and discussion
Characterization of TiO2 nanoparticles
A representative transmission electron microscopic image of 
the TiO2 nanoparticles is shown in Figure 1. The particles had 
a spherical shape with a diameter of about 25 nm. The size 
distribution of the TiO2 nanoparticles is shown in Figure 2. 
The particles had dimensions suitable for escaping rapid renal 
excretion, as well as avoiding components of the reticular 
endothelial system, thus facilitating potentially passive tar-
geting of drugs to tumors via the enhanced permeation and 
retention effect and increasing drug accumulation in tumor 
cells after endocytosis.16
Drug carrier role of TiO2 nanoparticles
Previous investigations showed that doxorubicin has three 
potential metal binding sites. One is the nitrogen atom in 
the sugar moiety and the other two are the chelating sites of 
the quinone and the phenolic oxygens on both sides of the 
  anthracycline aromatic moiety.12 In the present study, we 
explored the ability of TiO2 nanoparticles to act as a drug 
carrier for loading doxorubicin. As shown in Figure 3A, we 
observed the color change of pure doxorubicin from red to 
pink during the loading process, indicating that doxorubicin 
molecules can form complexes with TiO2 nanoparticles, form-
ing DOX-TiO2 nanocomposites as a drug delivery system due 
to the interaction of doxorubicin with TiO2. Figure 3B shows 
a proposed schematic representation of doxorubicin loading International Journal of Nanomedicine 2011:6
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Figure 4 Cytotoxic effect of doxorubicin or DOX-TiO2 nanocomposites against 
the human sMMC-7721 hepatocarcinoma cells. 
Note: Data expressed as the mean ± standard deviation (n = 3). 
Abbreviations: DOX, doxorubicin; TiO2, titanium dioxide; Nps, nanoparticles.
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Figure 5 The IC50 of DOX, DOX-TiO2 nanocomposites for sMMC-7721 cells. 
Note: *P , 0.05, compared with free DOX. 
Abbreviations:  DOX,  doxorubicin;  DOX-TiO2,  titanium  dioxide-doxorubicin 
nanocomposites.
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onto the TiO2 nanoparticles. In addition, the surface charge is 
an important physicochemical property of nanomaterials, and 
the zeta potential is the common indicator. The zeta potential of 
the TiO2 nanoparticles (10 µg/mL) was negative (-26 mV) in 
pH 7.4 aqueous solution. When doxorubicin was loaded onto 
the TiO2 nanoparticles, the zeta potential decreased to -5 mV , 
indicating that doxorubicin can easily self-assemble onto the 
surface of TiO2 nanoparticles by electrostatic   interaction. 
The encapsulation efficiency and loading efficiency of the 
  doxorubicin-loaded TiO2 nanoparticles was assessed and 
calculated to be 60.46% ± 6.53% and 20.08% ± 2.14%, 
  respectively. The results show that DOX-TiO2 nanocomposites 
may act efficiently as an anticancer drug delivery carrier.
Anticancer efficacy enhancement and side 
effect attenuation
To explore further the anticancer efficiency of the novel drug 
delivery system based on DOX-TiO2 nanocomposites, we 
cultured human hepatocarcinoma SMMC-7721 cells with 
free doxorubicin at different concentrations (0, 0.125, 0.25, 
0.5, and 1 µg/mL) and with DOX-TiO2 nanocomposites 
with equivalent doxorubicin concentrations for 48 hours. 
  Cytotoxicity was estimated by MTT assay and is shown in 
Figure 4. Cytotoxicity testing of a nanomaterial is the first-
level evaluation before its biomedical application. When 
treated by TiO2 nanoparticles (10 µg/mL ), about 95% of the 
cells survived (Figure 4, red line), which is consistent with 
our previous report.15 This result suggests lack of cytotoxicity 
for TiO2 nanoparticles, thus ensuring a wide potential range 
of applications in the field of biomedical science and cancer 
therapy. Compared with doxorubicin alone (Figure 4, pink 
line), the viability of SMMC-7721 cells treated by DOX-TiO2 
nanocomposites markedly decreased (Figure 4, blue line). Our 
results also indicate that lethality increases with increasing 
concentrations of DOX, suggesting a dose-dependent effect 
in vitro. This increased cytotoxicity may be due to improved 
doxorubicin cellular uptake by DOX-TiO2 nanocomposites 
through the endocytosis pathway, which is a common char-
acteristic of nanoparticle-based drug delivery systems.17 
Therefore, a sufficiently high concentration of doxorubicin 
can be generated within tumor cells by TiO2 nanoparticles, 
thereby greatly promoting the cytotoxic effects.
The IC50 value, ie, the concentration of a drug that inhibits 
cell growth by 50% in different treatments, was determined 
from the above dose response. As shown in Figure 5, the IC50 
value for free doxorubicin in the tumor cells was 0.32 µg/mL, 
and DOX-TiO2 nanocomposites could alter the IC50 value to 
0.20 µg/mL. Considering that a high dose of doxorubicin may 
lead to serious side effects, especially congestive heart failure,2 
the lower IC50 for the DOX-TiO2 nanocomposite drug delivery 
system could improve therapeutic efficacy without high usage 
of doxorubicin and minimize its toxic side effects.
expression of Bax, Bcl-2, and caspase 3 
proteins
Nuclear DNA is the main subcellular site of doxorubicin 
action for its antitumor activity. Doxorubicin can efficiently 
accumulate in the cell nucleus, intercalate DNA, and act as a 
cytostatic and apoptotic agent in tumor cells. The production 
of free radicals and oxidative stress is also closely involved in 
the action of doxorubicin, in terms of both anticancer and toxic 
effects.18 To explore the possible signaling pathways through 
which DOX-TiO2 nanocomposites enhance anticancer efficacy 
and attenuate side effects, we examined changes in the expres-
sion levels of apoptosis-regulating proteins, including Bax, 
Bcl-2, and caspase 3, by Western blot. As shown in   Figure 6, International Journal of Nanomedicine 2011:6
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Figure 6 expression of Bax, Bcl-2, and caspase 3 protein (A) and the Bax/Bcl-2 ratio (B) 
in the human sMMC-7721 hepatocarcinoma cells by Western blot after treatment with 
doxorubicin and/or TiO2 nanoparticles for 48 hours. Line 1, control; line 2, incubated 
with 10 µg/mL TiO2 nanoparticles; line 3, incubated with 0.5 µg/mL doxorubicin; line 4, 
incubated with 0.5 µg/mL doxorubicin and 10 µg/mL TiO2 nanoparticles. 
Abbreviations: DOX, doxorubicin; TiO2, titanium dioxide; Nps, nanoparticles.
Figure 7 Schematic illustration of the possible process of the anticancer efficacy enhancement and side effect attenuation by the drug delivery system based on TiO2 
nanoparticles for DOX. 
Abbreviations: DDs, drug delivery system; TiO2, titanium dioxide; DOX, doxorubicin; Nps, nanoparticles.
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when the human SMMC-7721   hepatocarcinoma cells were 
treated with doxorubicin and DOX-TiO2 for 48 hours, levels 
of Bax and caspase 3 protein were significantly upregulated 
compared with the other groups. Meanwhile, levels upregu-
lated by DOX-TiO2 were slightly higher than those upregulated 
by doxorubicin (P , 0.05). However, they were not obviously 
altered when the cells were treated with TiO2 nanoparticles 
alone (P . 0.05). In contrast, compared with the control 
group, levels of Bcl-2 protein in cells treated with doxorubi-
cin and DOX-TiO2 were both significantly downregulated. 
  Furthermore, the level of Bcl-2 in cells treated with DOX-TiO2 
was lower than that in cells treated with doxorubicin, and was 
not obviously altered when the cells were treated with TiO2 
nanoparticles alone (P . 0.05). The ratio of Bax/Bcl-2 protein 
expression increased dramatically when the SMMC-7721 cells 
were treated with DOX-TiO2 nanocomposites in our study.
Sensitivity of cells to an apoptotic stimulus is determined 
by the relative ratio of proapoptotic and antiapoptotic mem-
bers of the Bcl-2 family, ie, the mitochondrial-related death 
switch.19 Upregulated Bax leads to disruption of the integ-
rity of the mitochondrial membrane, resulting in caspase 3 
activation. Caspase activation is generally considered to be 
the hallmark of apoptosis, and caspase 3 is the main effec-
tor caspase that is involved in apoptosis.20 Thus, the ratio of 
Bax/Bcl-2 might be a critical factor in the cell threshold for 
undergoing apoptosis induced by DOX-TiO2. These findings 
strongly suggest that DOX-TiO2 nanocomposites enhance 
anticancer efficacy and reduce side effects by inducing 
apoptosis in a caspase-dependent manner.
Figure 7 schematically illustrates the possible pro-
cesses by which this novel drug delivery system based on 
TiO2 nanoparticles conjugated with doxorubicin enhances 
anticancer efficacy and attenuates side effects. Firstly, 
doxorubicin can be easily self-assembled onto the surface International Journal of Nanomedicine
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of TiO2   nanoparticles by forming complexes with titanium, 
a transition metal. In this way, TiO2 nanoparticles can load 
large amounts of doxorubicin molecules and carry them 
into cells, increasing the intracellular concentration of 
doxorubicin dramatically, thus enhancing the suppression of 
proliferation of the cancer cells. Therefore, this drug delivery 
system increases the therapeutic concentration of doxorubi-
cin inside cancer cells, enhancing the efficiency of the drug 
dose, decreasing the IC50, and accordingly attenuating side 
effects, which indicates tremendous potential for application 
in cancer therapy. Apoptosis, the preferred therapeutic mode 
for killing cancer cells, is induced synergistically, resulting 
in marked improvement in anticancer activity.
Conclusion
In this study we developed a drug delivery system for-
mulated by self-assembly of doxorubicin and TiO2 nano-
particles. The DOX-TiO2 nanocomposites increased the 
accumulation of doxorubicin in tumor cells, resulting in 
enhanced anticancer activity by inducing apoptosis in a 
caspase-dependent manner, with attenuation of the toxic 
side effects of doxorubicin. These characteristics show that 
this novel drug delivery system based on TiO2 nanoparticles 
conjugated with doxorubicin is a promising strategy for 
future clinical practice.
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